- Investing Ideas
- U.S. Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
U.S. Pharmaceuticals & Biotech Solid Balance Sheet and Fundamentals
Results
3
0 new
High return on equity, past performance and sound balance sheet.
3 companies
Rigel Pharmaceuticals
Market Cap: US$716.4m
A biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
RIGL
US$40.26
7D
3.1%
1Y
113.7%
Exelixis
Market Cap: US$14.0b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$55.53
7D
2.3%
1Y
25.7%
Catalyst Pharmaceuticals
Market Cap: US$3.8b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$31.50
7D
0.1%
1Y
50.4%